Welcome to our dedicated page for Apyx Medical Corporation news (Ticker: APYX), a resource for investors and traders seeking the latest updates and insights on Apyx Medical Corporation stock.
Apyx Medical Corporation (NASDAQ: APYX) is a cutting-edge energy technology company that develops, manufactures, and markets advanced medical devices for the cosmetic and surgical markets globally. The company operates through two primary segments: Advanced Energy and Original Equipment Manufacturing (OEM).
Under the Renuvion brand, Apyx Medical offers proprietary helium plasma and radiofrequency technology, which is widely used in cosmetic surgery. This innovative technology provides surgeons with the ability to apply controlled heat to tissues, optimizing results in procedures such as body contouring and liposuction. The J-Plasma system, marketed for surgical applications within hospitals, minimizes unintended tissue trauma during surgical operations.
Recent achievements underline Apyx Medical's commitment to advancing medical technology. In the third quarter of 2023, the company reported a 31% year-over-year increase in total revenue, highlighted by a 39% increase in Advanced Energy sales. Significant strides were made in developing the Apyx One Generator and associated accessories, which have seen robust global demand.
From a financial perspective, Apyx Medical continues to strengthen its position. For the year ending December 31, 2023, the company secured a new five-year credit agreement with Perceptive Advisors, providing up to $45 million in capital. This new agreement enhances the company's financial flexibility and supports its growth strategy.
The company's OEM segment collaborates with other medical device manufacturers to design, develop, and produce electrosurgical generators and related accessories. This segment saw a 14% year-over-year growth in revenue during the first three quarters of 2023.
Apyx Medical remains focused on leveraging regulatory clearances and expanding its market reach. Noteworthy is its active participation in industry conferences, such as the American Academy of Cosmetic Surgery’s Annual Meeting, where it showcases its innovative products and clinical findings. The company continues to invest in research and development to enhance its product offerings, and is committed to maintaining rigorous safety and efficacy standards, supported by an extensive portfolio of clinical evidence.
In summary, Apyx Medical Corporation is at the forefront of medical energy technology, providing innovative solutions that elevate patient care in both cosmetic and surgical markets. With a robust financial outlook, strategic industry partnerships, and a continuous drive for product excellence, Apyx Medical is poised for sustained growth and market leadership.
Apyx Medical Corporation (NASDAQ:APYX) reported its Q4 and full year 2022 results, revealing a 25% decline in total revenue to $12.6 million for Q4, and a 8% decrease for the year to $44.5 million. Advanced Energy revenue dropped 30% year-over-year to $10.5 million in Q4, while OEM revenue increased 15%. The company experienced a net loss of $6.0 million for Q4, worsening from $2.0 million a year earlier, and a loss of $23.2 million for 2022. Looking ahead, Apyx anticipates 2023 revenue between $58.0 million and $61.0 million, indicating a potential growth of 30% to 37% year-over-year. Key developments included the launch of a new marketing campaign and a secured $35 million credit facility.
Apyx Medical Corporation (NASDAQ:APYX) has received 510(k) clearance from the U.S. FDA for its Renuvion APR Handpiece. This device is approved for delivering radiofrequency energy and/or helium plasma for soft tissue coagulation and contraction, specifically subcutaneous tissue. CEO Charlie Goodwin emphasized this clearance underscores Renuvion's safety and effectiveness. Apyx is currently seeking an additional indication for use following liposuction, which remains under FDA review. The company specializes in advanced energy technology, aiming to elevate patient outcomes in cosmetic and surgical markets.
Apyx Medical Corporation has secured a new five-year credit facility worth up to
Apyx Medical Corporation (NASDAQ: APYX) announced it will release its financial results for Q4 and fiscal year 2022 before the market opens on March 16th. Management will hold a conference call at 8:00 a.m. ET that same day to discuss these results and answer questions. Interested parties can access the call by dialing 877-407-8289 (international: 201-689-8341) using access code 13736530. The call will also be available via a live webcast. Apyx Medical specializes in advanced energy technology, particularly in helium plasma products marketed as Renuvion and J-Plasma for cosmetic and surgical applications.
Apyx Medical Corporation (NASDAQ:APYX) announced that its Renuvion neck laxity procedure will be featured on 'The Balancing Act' talk show on Lifetime on February 13, 2023, at 7:30 am ET/PT. The segment will showcase a minimally invasive neck procedure performed by Dr. Charles J. Galanis, highlighting its effectiveness in reducing sagging skin. Renuvion is the only FDA-cleared product for addressing neck and chin skin laxity, offering patients minimal downtime and cost-effectiveness. The segment will also re-run on February 21, 2023, with additional broadcasts throughout the year.
Apyx Medical Corporation (NASDAQ:APYX) has submitted a 510(k) premarket notification to the U.S. FDA for its Renuvion APR Handpiece, aiming to expand its use for coagulating subcutaneous soft tissues after liposuction. Supported by a clinical study and extensive evidence, the submission indicates that no new risks are associated with Renuvion when used post-liposuction. CEO Charlie Goodwin expressed optimism about receiving the FDA clearance, which may alleviate existing limitations outlined in the Medical Device Safety Communication.
Apyx Medical Corporation (NASDAQ: APYX) has launched the Apyx One Console, an advanced energy system now available to U.S. medical professionals. This multi-functional generator integrates Renuvion technology with monopolar and bipolar energy capabilities. Key features include adaptive touch screens, cloud connectivity, and a four-year warranty. Designed in collaboration with leading physicians, the Apyx One Console aims to enhance user experience and provides an upgrade option for existing customers. This product reinforces Apyx's commitment to innovation in the cosmetic surgery market.
Apyx Medical Corporation (NASDAQ:APYX) reported preliminary revenue results for Q4 and full year 2022, revealing a total revenue range of $12.1 to $12.5 million for Q4, a decline of 28% to 26% year-over-year. For the full year, revenue ranged from $44.0 to $44.4 million, declining by 9% to 8% year-over-year. The Advanced Energy segment showed significant declines of 33% to 30% in Q4 and 15% to 14% for the full year, while OEM revenue grew 12% in Q4 and 37% for the year. Despite challenges, the company plans for over 35% growth in 2023 driven by regulatory objectives.
Apyx Medical Corporation (NASDAQ: APYX) announces the launch of its inaugural direct-to-consumer campaign, #ThisIsMe, aimed at promoting its Renuvion technology for minimally invasive procedures. The campaign features national digital advertising and social media initiatives targeting consumers seeking aesthetic improvements. This campaign follows recent FDA clearances for Renuvion, specifically for treating loose skin on the chin and neck. The marketing efforts are designed to enhance brand awareness and highlight the technology's unique benefits, positioning Renuvion as a leader in cosmetic procedures.
Apyx Medical Corporation (NASDAQ:APYX) announced its participation in the Piper Sandler 34th Annual Healthcare Conference on November 30 at 11:00 a.m. ET, held at the Lotte New York Palace. Management will engage in a fireside chat, accessible via a live audio webcast on the Company's investor relations website.
Apyx Medical specializes in advanced energy technologies, notably its Helium Plasma Technology branded as Renuvion® for cosmetic and J-Plasma® for surgical markets, offering innovative solutions for tissue management.
FAQ
What is the current stock price of Apyx Medical Corporation (APYX)?
What is the market cap of Apyx Medical Corporation (APYX)?
What does Apyx Medical Corporation specialize in?
What are the key product lines of Apyx Medical?
What recent financial achievements has Apyx Medical reported?
What significant recent projects has Apyx Medical undertaken?
Who are the typical customers for Apyx Medical's Renuvion technology?
What recent strategic financial move has Apyx Medical made?
How does Apyx Medical contribute to the OEM market?
What role does research and development play at Apyx Medical?
Where can I find more information about Apyx Medical's products?
What industry events does Apyx Medical participate in?
